Skip to main content

Table 4 Results of a joint-based analysis

From: Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT

  TJC SJC SUV TJC SJC SUV TJC SJC SUV
  (0M) (0M) (0M) (3M) (3M) (3M) (6M) (6M) (6M)
Rt shoulder 1 0 1.71±1.11 2 0 1.68±0.76 1 0 1.65±0.60
Lt shoulder 0 0 2.06±1.31 1 0 2.06±1.20 1 0 2.11±1.07
Rt elbow 1 2 1.63±1.05 3 3 1.48±0.77 5* 4 1.46±0.58
Lt elbow 2 3 2.05±1.50 5 4 1.70±1.15 5 5 1.64±1.06*
Rt wrist 7 9 2.69±1.24 2* 8 2.30±1.44 3 3* 1.92±1.11
Lt wrist 6 8 2.49±1.44 2 4 2.23±1.57 1* 2* 1.96±1.17
Rt knee 7 9 2.90±1.89 2* 4 1.98±0.82* 4 5 1.89±0.90*
Lt knee 7 7 2.58±1.82 1* 4 1.90±1.22* 2 5 1.84±1.05*
Rt hip 0 0 1.47±0.50 0 0 1.53±0.36 0 1 1.55±0.50
Lt hip 1 0 1.54±0.59 0 0 1.56±0.33 0 1 1.43±0.43
Rt ankle 4 5 1.95±1.21 3 3 1.67±0.99 4 3 1.55±0.91
Lt ankle 5 7 1.95±1.21 4 3 1.75±1.08 5 5 1.79±0.96
  1. The data are presented as the mean ± S.D.. *indicates a significant difference compared with the value observed at baseline (Wilcoxon signed rank-sum test, p < 0.05).